R-2-hydroxyglutarate-mediated inhibition of KDM4A compromises telomere integrity

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Gene mutations affecting cellular metabolism are common in cancers.
• IDH1/2 mutations producing R-2HG are early events in low-grade gliomas.
• R-2HG inhibits alpha-ketoglutarate (αKG)-dependent enzymes, including KDM4A.

Purpose of the Study:

• To elucidate the molecular mechanism linking R-2HG production to gliomagenesis.
• To investigate the role of KDM4A inhibition in IDH-mutant gliomas.
• To understand how R-2HG impacts cellular processes like senescence and telomere maintenance.

Main Methods:

• Treatment with R-2HG and assessment of cellular senescence.
• Analysis of telomeric dysfunction in cells expressing mutated IDH1 or treated with R-2HG.
• Investigating KDM4A localization and its effect on telomeric H3K9(me3).
• Studying replication fork progression and the role of SMARCAL1.

Main Results:

• R-2HG treatment induces p53-dependent cellular senescence.
• IDH1 mutation or R-2HG exposure leads to telomeric dysfunction via KDM4A inhibition.
• KDM4A regulates H3K9(me3) at telomeres; R-2HG reduces replication fork progression.
• SMARCAL1 depletion rescues telomeric defects caused by R-2HG or KDM4A depletion.

Conclusions:

• IDH1/2 mutations promote R-2HG production, inhibiting KDM4A.
• This inhibition causes telomeric DNA replication defects and dysfunction.
• The findings establish a model where KDM4A inhibition contributes to gliomagenesis through genomic instability.